Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 11471768

Epilepsy.

S C Schachater
View original source ↗Export metadata ↓

Abstract

The successful management of epilepsy requires a thorough and individualized approach that accurately establishes the patient's seizure type(s) and, when appropriate, epilepsy syndrome. Selection of pharmacologic and nonpharmacologic therapy should be rational and tailored to each patient. In this manner, clinicians are able to take advantage of new treatments to minimize the impact of seizures, treatment side effects, and epilepsy-related psychosocial difficulties on their patients, thereby enabling them to function in society at the highest possible level.

Explore related subjects

AnticonvulsantsBrainElectric Stimulation TherapyEpilepsyHumansVagus NerveJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

S C Schachater. 2001. Epilepsy.. https://doi.org/10.1016/s0733-8619(05)70005-0

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2003

The treatment of epilepsy in developing countries: where do we go from here?

Epilepsy is the most common serious neurological disorder and is one of the world's most prevalent noncommunicable diseases. As the understanding of its physical and social burden has increased it has moved higher up the world health agenda. Over four-fifths of the 50 million people with epilepsy are thought to be in developing countries; much of this condition results from preventable causes. Around 90% of people with epilepsy in developing countries are not receiving appropriate treatment. Consequently, people with epilepsy continue to be stigmatized and have a lower quality of life than people with other chronic illnesses. However, bridging the treatment gap and reducing the burden of epilepsy is not straightforward and faces many constraints. Cultural attitudes, a lack of prioritization, poor health system infrastructure, and inadequate supplies of antiepileptic drugs all conspire to hinder appropriate treatment. Nevertheless, there have been successful attempts to provide treatment, which have shown the importance of community-based approaches and also indicate that provision for sustained intervention over the long term is necessary in any treatment programme. Approaches being adopted in the demonstration projects of the Global Campaign Against Epilepsy--implemented by the International League Against Epilepsy, the International Bureau for Epilepsy, and the World Health Organization--may provide further advances. Much remains to be done but it is hoped that current efforts will lead to better treatment of people with epilepsy in developing countries.

Anticonvulsants↗
PubMed2002

Development of a polymeric nanoparticulate drug delivery system. In vitro characterization of nanoparticles based on sugar-containing conjugates.

This paper reports the synthesis of polymeric nanoparticles from a sugar-containing conjugate for liver-specific drug delivery. The conjugate was composed of lactobionic acid, diamine-terminated poly(ethylene glycol) and cholic acid (abbreviated as LEC). The conjugate was characterized by (1)H NMR and FT-IR spectroscopy measurements. In aqueous media, the conjugate can self-assemble to form core-shell type nanoparticles, and the formation of a core-shell structure was observed by fluorescence spectroscopy. The critical association concentration (CAC) of the LEC conjugate nanoparticles was determined from fluorescence excitation spectra to be 0.05 g/l. The LEC nanoparticles were mostly spherical with sizes ranging from 10 to 30 nm. Clonazepam (CNZ) was used as a model hydrophobic drug, and was incorporated into the hydrophobic core of the nanoparticles. CNZ was released more slowly at a higher drug loading due to drug crystallization.

Anticonvulsants↗
PubMed2002

The co-morbidity of depression and epilepsy: epidemiology, etiology, and treatment.

Co-morbid depression is common in patients with epilepsy and is often undiagnosed. The manifestation of depression in epilepsy is multifaceted with many interacting neurobiological and psychosocial determinants, including clinical features of epilepsy (seizure frequency, type, foci, or lateralization of foci) and neurochemical or iatrogenic mechanisms. Depression is reported more frequently in patients with temporal lobe epilepsy (TLE) and left-sided foci, although not all studies support this finding. In patients with depression and epilepsy, optimal control of seizures should be attained first and foremost with appropriate anticonvulsant treatments including antiepileptic drugs (AEDs) and vagus nerve stimulation (VNS) therapy. Some anticonvulsant treatments (VNS, valproate, carbamazepine, lamotrigine, and gabapentin) have demonstrated mood improvement in epilepsy patients and may have therapeutic potential for this patient population. When antidepressants are necessary to treat depression in patients with epilepsy, selective serotonin reuptake inhibitors (SSRIs) and multireceptor antidepressants are considered first-line treatments. Electroconvulsive therapy is not contraindicated for treatment-resistant or psychotic depression. Depression must be recognized, diagnosed, and adequately treated in patients with epilepsy.

Anticonvulsants↗